Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664
White MV, Silvia S, Hollis K, Wooddell M, Hogue S. Differences in anaphylaxis-related risks by school grade level: findings from the EpiPen4Schools® survey. Poster presented at the 2015 ASCIA Conference; September 2015. Adelaide, Australia. [abstract] Intern Med J. 2015 Sep 3; 45(Suppl 4):3. doi: 10.1111/imj.12869